RealZE
Research type
Research Study
Full title
RealZE: Real-Word Evidence retrospective study on the characteristics, treatment patterns, and outcomes of patients newly diagnosed with advanced epithelial high-grade serous ovarian cancer.
IRAS ID
329948
Contact name
Shibani Nicum
Contact email
Sponsor organisation
GSK
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Ovarian cancer is a major women-health problem worldwide, being the first most lethal
gynecological tumor and the seventh most lethal cancer in women. About 85–90%
of all ovarian cancers are Epithelial Ovarian Cancers (EOC), and around 70% of them are high grade serous (HGS-EOC).In recent years, increasing knowledge of the genetic and molecular makeup of solid tumors has led to the availability of an ever-growing number of targeted therapies to treat cancer. For EOC patients, the targeted therapy revolution has been led by Poly ADP-ribose polymerase inhibitors (PARPi), specially for patients with homologous recombination deficiency (HRD) and/or somatic or germline BRCA gene mutations. Nevertheless, and despite the important progress made with PARPi, more alternatives are needed to continue improving the outcomes of patients with EOC. For this purpose, it is essential to have a clear picture of the disease and its real-world treatment patterns. The present study will leverage advanced Natural Language Processing (NLP), Machine Learning (ML), and Data Analytics provided by EHRead® to systematically extract and analyze large amounts of clinical data from multiple hospital sites. Thus, it offers a unique opportunity to perform a comprehensive characterization of patients diagnosed with EOC and their treatment patterns across a wide range of clinical settings.REC name
London - Bloomsbury Research Ethics Committee
REC reference
24/LO/0268
Date of REC Opinion
15 May 2024
REC opinion
Further Information Favourable Opinion